{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:47:59Z","timestamp":1782841679900,"version":"3.54.5"},"reference-count":41,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Myopia is increasingly prevalent worldwide, with projections indicating that nearly 50% of the global population may have myopia by 2050. This surge poses significant concerns due to its impact on vision and quality of life and its link to a range of blinding diseases, including myopic macular degeneration, glaucoma, and retinal detachment. Current pharmacologic and optical interventions offer limited effectiveness in slowing myopia progression, highlighting the urgent need for more effective treatments.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This study aims to examine the combined effect of bright light therapy and low-dose atropine on myopic progression.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This is a single-site, 2-arm, single-masked (examiner-masked) randomized controlled trial to compare the effectiveness of low-dose atropine alone and its combination with bright light therapy in retarding myopia progression. The study protocol has been approved by the institutional review boards of Hong Kong Polytechnic University (HSEARS 20180829002-05) and the University of Hong Kong and Hospital Authority Hong Kong West Cluster (UW 20-362). Schoolchildren with myopia aged 7 to 12 years who have not undergone any previous myopic control intervention will be recruited and randomly allocated into 2 groups (n=67 per group) after baseline measurements. Both groups will receive 0.01% atropine twice daily for 24 months. The combination treatment group will also receive a high-intensity lamp for bright light therapy. The primary and secondary outcome measures will be the changes in cycloplegic autorefraction in spherical equivalent refraction and axial length, respectively, measured every 6 months over 2 years from baseline.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The project was funded in January 2019. The recruitment process started on March 21, 2023, and was completed on February 2, 2024. Data collection is expected to be completed in April 2026.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This study will provide new information on whether the combination of bright light therapy and low-dose atropine is more effective than atropine alone in slowing down myopia progression. It will also assess the effectiveness of low-dose atropine used twice daily. Combining bright light therapy and atropine could become a new treatment option if shown to be effective. New data on the effectiveness of using atropine twice daily might also expand available treatment options.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/90893","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T13:30:07Z","timestamp":1772026207000},"page":"e90893-e90893","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of Low-Dose Atropine Combined With Bright Light Therapy for Controlling Myopic Eye Growth in Schoolchildren: Study Protocol for a Randomized Controlled Trial"],"prefix":"10.2196","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7561-9121","authenticated-orcid":false,"given":"Dennis Yan-Yin","family":"Tse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4066-5061","authenticated-orcid":false,"given":"Martin Ming-Leung","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0350-4020","authenticated-orcid":false,"given":"Ying","family":"Hon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2709-927X","authenticated-orcid":false,"given":"Lai Ming","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2057-9374","authenticated-orcid":false,"given":"Wai Ching","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6255-2941","authenticated-orcid":false,"given":"Kendrick Co","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4197-1423","authenticated-orcid":false,"given":"Xiujuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8763-9385","authenticated-orcid":false,"given":"Desmond Man Kit","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1825-2516","authenticated-orcid":false,"given":"Andy Chi Wai","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3511-5620","authenticated-orcid":false,"given":"Thomas Chuen","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6808-5018","authenticated-orcid":false,"given":"Carly Siu Yin","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6830-4196","authenticated-orcid":false,"given":"Tina Jinxiao","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4548-3574","authenticated-orcid":false,"given":"Ian","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1938-8397","authenticated-orcid":false,"given":"Chi Ho","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6978-0963","authenticated-orcid":false,"given":"Rachel Ka Man","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4862-777X","authenticated-orcid":false,"given":"Christopher Kai Shun","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"issue":"5","key":"R1","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050","volume":"123","author":"Holden","journal-title":"Ophthalmology"},{"issue":"5","key":"R2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.62.5.2","article-title":"IMI impact of myopia","volume":"62","author":"Sankaridurg","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"R3","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.61.4.49","article-title":"The complications of myopia: a review and meta-analysis","volume":"61","author":"Haarman","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1125000","article-title":"Effectiveness of myopia control interventions: a systematic review of 12 randomized control trials published between 2019 and 2021","volume":"11","author":"Lanca","journal-title":"Front Public Health"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2013.05.004","article-title":"Light levels, refractive development, and myopia--a speculative review","volume":"114","author":"Norton","journal-title":"Exp Eye Res"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2017.09.004","article-title":"The epidemics of myopia: aetiology and prevention","volume":"62","author":"Morgan","journal-title":"Prog Retin Eye Res"},{"issue":"11","key":"R7","doi-asserted-by":"publisher","first-page":"5348","DOI":"10.1167\/iovs.09-3419","article-title":"The effect of ambient illuminance on the development of deprivation myopia in chicks","volume":"50","author":"Ashby","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"R8","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1167\/iovs.11-8652","article-title":"Protective effects of high ambient lighting on the development of form-deprivation myopia in rhesus monkeys","volume":"53","author":"Smith","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"R9","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1167\/iovs.16-20402","article-title":"Bright light suppresses form-deprivation myopia development with activation of dopamine D1 receptor signaling in the ON pathway in retina","volume":"58","author":"Chen","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2012.08.004","article-title":"Ambient illuminance, retinal dopamine release and refractive development in chicks","volume":"103","author":"Cohen","journal-title":"Exp Eye Res"},{"issue":"7","key":"R11","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/eye.2012.49","article-title":"Comparison of measurements of time outdoors and light levels as risk factors for myopia in young Singapore children","volume":"26","author":"Dharani","journal-title":"Eye (Lond)"},{"issue":"8","key":"R12","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1136\/bjo.2008.150979","article-title":"Outdoor activity and myopia in Singapore teenage children","volume":"93","author":"Dirani","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"R13","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.ophtha.2017.12.011","article-title":"Myopia prevention and outdoor light intensity in a school-based cluster randomized trial","volume":"125","author":"Wu","journal-title":"Ophthalmology"},{"issue":"6","key":"R14","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1167\/iovs.11-9091","article-title":"Time outdoors and physical activity as predictors of incident myopia in childhood: a prospective cohort study","volume":"53","author":"Guggenheim","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"R15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2024-002044","article-title":"Effectiveness of bright light therapy and combination with myopic defocus for controlling myopic eye growth in schoolchildren: study protocol for a randomised controlled trial (phase 1)","volume":"10","author":"Hon","journal-title":"BMJ Open Ophthalmol"},{"issue":"1","key":"R16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-Concentration Atropine for Myopia Progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control","volume":"126","author":"Yam","journal-title":"Ophthalmology"},{"issue":"3","key":"R17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/ICL.0000000000000677","article-title":"Biological mechanisms of atropine control of myopia","volume":"46","author":"Upadhyay","journal-title":"Eye Contact Lens"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2017.06.003","article-title":"Dopamine signaling and myopia development: what are the key challenges","volume":"61","author":"Zhou","journal-title":"Prog Retin Eye Res"},{"issue":"5","key":"R19","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1001\/jama.2025.4486","article-title":"SPIRIT 2025 statement: updated guideline for protocols of randomized trials","volume":"334","author":"Chan","journal-title":"JAMA"},{"issue":"9","key":"R20","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/ceo.14148","article-title":"Low-concentration atropine eyedrops for myopia control in a multi-racial cohort of Australian children: a randomised clinical trial","volume":"50","author":"Lee","journal-title":"Clin Exp Ophthalmol"},{"issue":"1","key":"R21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jamapsychiatry.2015.2235","article-title":"Efficacy of bright light treatment, fluoxetine, and the combination in patients with nonseasonal major depressive disorder: a randomized clinical trial","volume":"73","author":"Lam","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"R22","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1017\/s1092852900019611","article-title":"Light therapy for seasonal and nonseasonal depression: efficacy, protocol, safety, and side effects","volume":"10","author":"Terman","journal-title":"CNS Spectr"},{"issue":"9","key":"R23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075893","article-title":"The acute side effects of bright light therapy: a placebo-controlled investigation","volume":"8","author":"Botanov","journal-title":"PLoS One"},{"issue":"2","key":"R24","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/s0002-9394(14)73874-7","article-title":"Ophthalmologic examination of patients with seasonal affective disorder, before and after bright light therapy","volume":"119","author":"Gallin","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"R25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1176\/ajp.155.2.293","article-title":"Side effects of short-term 10,000-lux light therapy","volume":"155","author":"Kogan","journal-title":"Am J Psychiatry"},{"issue":"6","key":"R26","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1001\/jamaophthalmol.2017.1091","article-title":"Efficacy and adverse effects of atropine in childhood myopia: a meta-analysis","volume":"135","author":"Gong","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"R27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-Concentration Atropine for Myopia Progression (LAMP) study","volume":"126","author":"Yam","journal-title":"Ophthalmology"},{"issue":"2","key":"R28","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","journal-title":"J Biomed Inform"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100923","article-title":"Efficacy in myopia control","volume":"83","author":"Brennan","journal-title":"Prog Retin Eye Res"},{"issue":"16","key":"R30","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1038\/s41433-023-02534-8","article-title":"Myopia prevention and control in children: a systematic review and network meta-analysis","volume":"37","author":"Zhang","journal-title":"Eye (Lond)"},{"issue":"1","key":"R31","doi-asserted-by":"publisher","first-page":"101723","DOI":"10.1016\/j.clae.2022.101723","article-title":"Combined 0.01% atropine with orthokeratology in childhood myopia control (AOK) study: a 2-year randomized clinical trial","volume":"46","author":"Tan","journal-title":"Cont Lens Anterior Eye"},{"issue":"1","key":"R32","doi-asserted-by":"publisher","first-page":"12750","DOI":"10.1038\/s41598-020-69710-8","article-title":"Efficacy of combined orthokeratology and 0.01% atropine solution for slowing axial elongation in children with myopia: a 2-year randomised trial","volume":"10","author":"Kinoshita","journal-title":"Sci Rep"},{"issue":"5","key":"R33","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13051506","article-title":"Efficacy and safety of low-dose atropine on myopia prevention in premyopic children: systematic review and meta-analysis","volume":"13","author":"Lee","journal-title":"J Clin Med"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1227787","article-title":"Comparison of the efficacy and safety of different doses of atropine for myopic control in children: a meta-analysis","volume":"14","author":"Hou","journal-title":"Front Pharmacol"},{"issue":"1","key":"R35","doi-asserted-by":"publisher","first-page":"22267","DOI":"10.1038\/s41598-021-01708-2","article-title":"Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial","volume":"11","author":"Cui","journal-title":"Sci Rep"},{"issue":"3","key":"R36","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10384-021-00822-y","article-title":"Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study","volume":"65","author":"Hieda","journal-title":"Jpn J Ophthalmol"},{"issue":"11","key":"R37","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1001\/jamaophthalmol.2020.3820","article-title":"Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in Chinese children: a randomized clinical trial","volume":"138","author":"Wei","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"R38","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","article-title":"Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) study: continued versus washout: phase 3 report","volume":"129","author":"Yam","journal-title":"Ophthalmology"},{"issue":"6","key":"R39","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1001\/jama.2022.24162","article-title":"Effect of low-concentration atropine eyedrops vs placebo on myopia incidence in children: the LAMP2 randomized clinical trial","volume":"329","author":"Yam","journal-title":"JAMA"},{"issue":"4","key":"R40","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1080\/02713683.2022.2162925","article-title":"Low dose atropine in preventing the progression of childhood myopia: a randomised controlled trial","volume":"48","author":"Sharma","journal-title":"Curr Eye Res"},{"issue":"17","key":"R41","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1038\/s41433-025-03964-2","article-title":"Twice versus once daily application of 0.01% atropine for myopia control in children: a randomised controlled trial","volume":"39","author":"He","journal-title":"Eye (Lond)"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e90893","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:15:41Z","timestamp":1782839741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e90893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":41,"URL":"https:\/\/doi.org\/10.2196\/90893","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"article-number":"v15i5e90893"}}